FABBRONI, CHIARA
FABBRONI, CHIARA
Universita' degli Studi di MILANO
Long-term disease stability with bicalutamide in a man with aggressive angiomyxoma: case report and state of art
2024 A. Franza, E. Gusmaroli, C. Fabbroni, R. Vigorito, S. Pasquali, P.G. Casali, R.G. Sanfilippo
New targeted therapies in liposarcoma: state of art and future perspectives
2024 A. Franza, C. Fabbroni, S. Pasquali, P.G. Casali, R. Sanfilippo
TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group
2024 C. Fabbroni, G. Grignani, B. Vincenzi, E. Fumagalli, T.M. De Pas, A. Mazzocca, M.A. Pantaleo, A. Brunello, G.G. Baldi, A. Boglione, S. Fatigoni, A. Berruti, M. Giordano, A. Marrari, A.P. Dei Tos, A.S. Alberton, S. Aliberti, L. Carlucci, E. Rulli, P.G. Casali, R. Sanfilippo
Low-Grade Uterine Leiomyosarcoma Is Highly Sensitive to Hormonal Treatment
2023 R. Sanfilippo, M. Sbaraglia, C. Fabbroni, S. Croce, I. Ray-Coquard, F. Guermazi, B. Paolini, F. Blanc-Durand, A. Lecesne, V. Chiappa, A.P. Dei Tos, P.G. Casali
Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial
2023 R. Sanfilippo, N. Hindi, J. Cruz Jurado, J. Blay, A. Lopez-Pousa, A. Italiano, R. Alvarez, A. Gutierrez, I. Rincón-Perez, C. Sangalli, J.L. Pérez Aguiar, J. Romero, C. Morosi, M. Sunyach, C. Fabbroni, C. Romagosa, D. Ranchere-Vince, A.P. Dei Tos, P.G. Casali, J. Martin-Broto, A. Gronchi
Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma
2021 L. Mannarino, I. Craparotta, S. Ballabio, R. Frapolli, M. Meroni, E. Bello, N. Panini, M. Callari, R. Sanfilippo, P.G. Casali, M. Barisella, C. Fabbroni, S. Marchini, M. D'Incalci
Impact of pathological stratification on the clinical outcomes of advanced well‐differentiated/dedifferentiated liposarcoma treated with trabectedin
2021 C. Fabbroni, G. Fuca, F. Ligorio, E. Fumagalli, M. Barisella, P. Collini, C. Morosi, A. Gronchi, A.P.D. Tos, P.G. Casali, R. Sanfilippo
Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors
2020 R. Sanfilippo, C. Fabbroni, G. Fucà, E. Fumagalli, C. Morosi, M. Sbaraglia, A. Gronchi, P. Collini, A.P. Dei Tos, P.G. Casali
Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers
2020 G. Fucà, C. Fabbroni, R. Mancari, S. Manglaviti, G. Bogani, E. Fumagalli, R. Bertulli, C. Morosi, P. Collini, F. Raspagliesi, N. Colombo, P.G. Casali, R. Sanfilippo
Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study
2020 E. Zattarin, C. Fabbroni, F. Ligorio, A. Marra, C. Corti, O. Bernocchi, M. Sirico, D. Generali, G. Curigliano, G. Bianchi, G. Capri, L. Rivoltini, F. De Braud, C. Vernieri
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer : a Retrospective Comparison of Efficacy and Safety Profiles
2019 C. Vernieri, M. Prisciandaro, M. Milano, M.S. Cona, C. Maggi, M. Brambilla, A. Mennitto, C. Fabbroni, E. Farè, S. Cresta, L. Celio, G. Mariani, G. Bianchi, G. Capri, F. de Braud
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
2019 C. Vernieri, M. Milano, M. Brambilla, A. Mennitto, C. Maggi, M.S. Cona, M. Prisciandaro, C. Fabbroni, L. Celio, G. Mariani, G.V. Bianchi, G. Capri, F. de Braud